CAR therapies
Anixa Biosciences Nabs Option to Develop Cancer Vaccines With Verdi Solutions
If Anixa exercises its rights, Verdi and Anixa will collaborate on trials in the US, while Verdi will continue developing personalized vaccines in Europe.
Autolus Reports Steady Progress for Aucatzyl's US Launch, Anticipating European Approvals in 2025
The firm also said its partner BioNTech won't exercise its option rights for the CD19- and CD22-directed CAR T-cell therapy candidate AUTO1/22.
Cargo Therapeutics Suspends Last CAR T-Cell Therapy Program, Reduces Workforce by 90 Percent
The firm is also shuttering its allogeneic cell therapy platform and has tasked a new CEO to lead the company through a merger.
Precision Oncology Investments Continue Amid Stubborn Operational Difficulties, Survey Shows
Premium
Precision Medicine Online's 2024 survey shows biomarker test expansion but low clinical trial enrollment and long wait times for advanced therapies.
Legend, Janssen Will Invest $150M to Expand Carvykti Manufacturing in Europe
The firms expect that by expanding manufacturing capacity they can double the sales volume of Carvykti from 10,000 doses in 2025 to 20,000 doses in 2027.